Leo Mascarenhas, Division Chief and Director of Pediatric Hematology and Oncology at Cedars-Sinai Guerin Children, shared an article on LinkedIn:
“Hot of the press!
Some insight into the implications of stopping treatment in young sarcoma patients!”
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.
Authors: Leo Mascarenhas, et al.
